The estrogen receptor pathway has a critical role in breast cancer and, therefore, endocrine therapy, which blocks ER signaling, is highly effective; however, over time, a small subset of ER+ tumors recur due to the development of endocrine resistance [7,8]. This evidence concerns the gene ESR1 and breast carcinoma.